Samenvatting
Introduction: Migraine is a primary headache disorder, which imposes a major burden on the sufferers. The BECOME study (Burden of migrainE in specialist headache Centers treating patients with prOphylactic treatMent failurE) attempted to characterize and assess the prevalence, burden and healthcare resource utilization of migraine patients presenting in specialized headache centers in Europe and Israel. In this paper, we will describe the patient characteristics of the Belgian headache centers. Methods: The BECOME study was a prospective, non-interventional, cross-sectional study consisting of two parts. In the first part of the study, data were collected from subjects with a diagnosis of migraine. Subsequently, patients with ≥ 4 monthly migraine days (MMD) and ≥ 1 prior preventive treatment failure (PPTF) filled out validated questionnaires to assess the burden of disease. Results: In part 1 of the Belgian study population (N = 806), 45% of patients reported ≥ 8 MMD and 25% had failed ≥ 4 preventive treatments. In part 2 (N = 90), more than 90% of patients reported having severe impact of headache on daily life and having severe migraine-related disability. The impact was the highest for patients with ≥ 15 MMD, however, even within the patient population with < 8 MMD, the burden was significant. Almost 40% of the study population suffered from anxiety. Conclusions: These findings in the Belgian sample of the BECOME study demonstrate the substantial burden and unmet need for the management of difficult-to-treat migraine.
| Originele taal-2 | English |
|---|---|
| Pagina's (van-tot) | 1495-1503 |
| Aantal pagina's | 9 |
| Tijdschrift | Acta Neurologica Belgica |
| Volume | 123 |
| Nummer van het tijdschrift | 4 |
| Vroegere onlinedatum | 20 mei 2023 |
| DOI's | |
| Status | Published - aug. 2023 |
Bibliografische nota
Funding Information:Koen Paemeleire has received personal compensation from Allergan/Abbvie, Amgen/Novartis, Eli Lilly, Lundbeck and Teva for consulting, serving on a scientific advisory board, and/or speaking and is a clinical trial investigator for Amgen/Novartis (erenumab), Eli Lilly (galcanezumab), and Autonomic Technologies Inc. (sphenopalatine ganglion stimulation). Josefin Snellman has received personal compensation from Allergan/Abbvie, Amgen/Novartis, Eli Lilly, Lundbeck, Teva, Cefaly Technology, Autonomic Technologies Inc. and Man & Science for consulting, serving on a scientific advisory board, and/or speaking and is an investigator for Eli Lilly, Novartis, Lundbeck and Teva. Shannon Ritter and Josefin Snellman are full employees of Novartis. Jan Versijpt received personal fees and nonfinancial support from Teva, personal fees from Novartis and Lundbeck, and grants and nonfinancial support from Allergan/Abbvie.
Funding Information:
This study was funded by Novartis Pharma AG, Basel, Switzerland. The study sponsor participated in the study design, data collection, data review, data analysis and writing of the report.
Publisher Copyright:
© 2023, The Author(s) under exclusive licence to Belgian Neurological Society.
Copyright:
Copyright 2023 Elsevier B.V., All rights reserved.
Vingerafdruk
Duik in de onderzoeksthema's van 'Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study'. Samen vormen ze een unieke vingerafdruk.Citeer dit
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver